Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 83

Sort by

Sort Order Select

Journal Articles

A Prospective Economic Analysis of Canadian Cancer Trials Group Clc.2/Alliance A041202: A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia

Blood (2020) 136 (Supplement 1): 27–30.

https://doi.org/10.1182/blood-2020-136692

Published: 2020

Journal Articles

The Copy Number Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-142871

Published: 2020

Journal Articles

SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-136422

Published: 2020

Journal Articles

Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma

Michael D. Jain, MD PhD, Anca Prica, MD, Ryan D. Morin, PhD, Vishal Kukreti, MD, Robert Kridel, MDMPH,PhD, Rob C. Laister, PhD, Li Meng, Christopher Rushton, Miguel Alcaide, Rashmi S. Goswami, MD PhD, Jan Delabie, MD PhD, Jessica Weiss, Tony Panzarella, M.Sc., P.Stat, Michael Crump, MD, David W. Scott, MBChB, PhD, John Kuruvilla, MD

Blood (2019) 134 (Supplement_1): 2027.

https://doi.org/10.1182/blood-2019-131818

Published: 2019

Journal Articles

The Impact of Age on the Outcome of Primary Treatment for Classical Hodgkin's Lymphoma: 70 Years of Age Is a Clinical Relevant Cutpoint and the Most Important Predictor of Overall Survival

Lourdes Calvente, MD, Manjula Maganti, MSc, Mary Gospodarowicz, MD FRCPC, David C. Hodgson, MD MPH, FRCPC, Danielle Rodin, MD MPH, FRCPC, Alexander Sun, MD FRCPC, Richard Tsang, MD FRCPC, Robert Kridel, MDMPH,PhD, Vishal Kukreti, MD, Anca Prica, MD, Michael Crump, MD FRCPC, John Kuruvilla, MD

Blood (2019) 134 (Supplement_1): 1559.

https://doi.org/10.1182/blood-2019-130282

Published: 2019

Journal Articles

Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial

Franck Morschhauser, MD, Carmelo Carlo-Stella, MD, Fritz Offner, MD, Gilles A. Salles, MD PhD, Martin Hutchings, MD PhD, Gloria Iacoboni, MD, Anna Sureda, MD PhD, Michael Crump, MD, Joaquin Martinez-Lopez, MD PhD, Denise Thomas, MSc, Peter N Morcos, PharmD, Cristiano Ferlini, MD, Abiraj Keelara, PhD, Ann-Marie E Bröske, PhD, Marina Bacac, PhD, Natalie Dimier, PhD, Tom Moore, MBChB, Martin Weisser, MD, Michael Dickinson, MBBS,FRACP,FRCPA

Blood (2019) 134 (Supplement_1): 1584.

https://doi.org/10.1182/blood-2019-123949

Published: 2019

Journal Articles

Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation

Vinita Dhir, BSc, Lara Zibdawi, Harminder K Paul, MSc, Osvaldo Espin-Garcia, PhD, Christine I Chen, MD, Michael Crump, MD FRCPC, Robert Kridel, MDMPH,PhD, Vishal Kukreti, MD, John Kuruvilla, MD, Donna E Reece, MD, Rodger E Tiedemann, MBChB, PhD, Suzanne Trudel, MD, Anca Prica, MD

Blood (2019) 134 (Supplement_1): 62.

https://doi.org/10.1182/blood-2019-131281

Published: 2019

Journal Articles

A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma

Sattva S Neelapu, MD, Frederick L. Locke, MD, Nancy L Bartlett, MD, Lazaros J Lekakis, MD, Patrick M Reagan, MD, David B. Miklos, MD PhD, Caron A. Jacobson, MD MMSc, Ira Braunschweig, MD, Olalekan O. Oluwole, MBBS, MPH, Tanya Siddiqi, MD, Yi Lin, MD PhD, Michael Crump, MD, John Kuruvilla, MD, Eric Van Den Neste, MD, Umar Farooq, MD, Lynn Navale, MS, Venita DePuy, PhD, Jenny J. Kim, MD MS, Christian Gisselbrecht, MD

Blood (2019) 134 (Supplement_1): 4095.

https://doi.org/10.1182/blood-2019-125792

Published: 2019

Journal Articles

Recurrent Patterns of Clonal Evolution in Relapsed-Refractory DLBCL Following Treatment with R-CHOP

Blood (2019) 134 (Supplement_1): 921.

https://doi.org/10.1182/blood-2019-127399

Published: 2019

Journal Articles

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

Mitchell Smith, MD PhD, Opeyemi Jegede, PhD, Samir Parekh, MD, Curtis A. Hanson, MD, Peter Martin, FRCPC, MD MS, Brian G. Till, MD, Michael Crump, MD FRCPC, John P. Leonard, MD, Jonathan W. Friedberg, MD, Brad S. Kahl, MD, Thomas E. Witzig, MD

Blood (2019) 134 (Supplement_1): 751.

https://doi.org/10.1182/blood-2019-129323

Published: 2019

Journal Articles

Event-Free Survival As a Surrogate for Overall Survival in Relapsed DLBCL after Autologous Transplant: A Subgroup Analysis of LY.12 and Coral

Sarit Assouline, MD, Shen Li, MD, Christian Gisselbrecht, MD, Patrick Fogarty, Annette E. Hay, Eric Van Den Neste, MD, Lois E. Shepherd, Norbert Schmitz, MD, Tara Baetz, Armand Keating, MD, Sue Robinson, MD, Matthew D. Seftel, FRCP,FRCPC,MPH,MD, Caterina Stelitano, Marina S. Djurfeldt, Ralph Meyer, Bingshu E. Chen, Michael Crump, MD FRCPC

Blood (2019) 134 (Supplement_1): 768.

https://doi.org/10.1182/blood-2019-124879

Published: 2019

Journal Articles

Evaluation of Unexplained Lymphadenopathy and Suspected Lymphoma in a Lymphoma Rapid Diagnostic Clinic

Shannon Nixon, NP, Manjula Maganti, MSc, Ksenia Bezverbnaya, BSc, John Kuruvilla, MD, Anca Prica, MD, Robert Kridel, PhD MD, Vishal Kukreti, MD, Patrick Gullane, MD, Michael Reedijk, MD, Melania Pintilie, MSc, Michael Crump, MD

Blood (2018) 132 (Supplement 1): 4739.

https://doi.org/10.1182/blood-2018-99-113515

Published: 2018

Journal Articles

Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma

Michael D. Jain, MD PhD, Ryan D. Morin, PhD BSc, MSc, Anca Prica, MD, Vishal Kukreti, MD, Robert Kridel, PhD MD, Rob C. Laister, PhD, Li Meng, Christopher Rushton, BSc, Miguel Alcaide, PhD, Rashmi S. Goswami, BSc, MD PhD FRCPC, Jan M.A. Delabie, MD PhD, Jessica Weiss, Tony Panzarella, M.Sc., P.Stat, Michael Crump, MD, David W. Scott, PhD MD, FRACP, FRCPA, John Kuruvilla, MD

Blood (2018) 132 (Supplement 1): 4610.

https://doi.org/10.1182/blood-2018-99-117333

Published: 2018

Journal Articles

Prognostic Significance of Neutrophil to Lymphocyte Ratio (NLR) in Relapsed/Refractory Aggressive Lymphoma Salvage Chemotherapy — Analysis of Canadian Cancer Trials Group (CCTG) ly.10 Trial

Mina Dehghani Mohammadabadi, MD, Annette E Hay, Lois E. Shepherd, Michael Crump, MD, Bingshu E. Chen, Tara Baetz, MD

Blood (2018) 132 (Supplement 1): 2980.

https://doi.org/10.1182/blood-2018-99-116316

Published: 2018

Journal Articles

Prolonged Overall Survival (OS) in a Subset of Responders to the Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL): Results of an International Multi- Center Phase I/II Experience

Ahmed Sawas, MD, John Kuruvilla, MD, Jennifer Kimberly Lue, MD, Changchun Deng, MD PhD, Jennifer E Amengual, MD, Francesca Montanari, MD, Kerry J Savage, BSc, MD MSc, Hager Elgedawe, Diego Villa, MD, Michael Crump, MD, Joseph M Connors, Owen A. O'Connor, MD, PhD

Blood (2018) 132 (Supplement 1): 2907.

https://doi.org/10.1182/blood-2018-99-117251

Published: 2018

Journal Articles

Treatment Outcomes in the Management of Lymphoblastic Lymphoma (LBL) in Adults: An Institutional Review

Rohan Kehar, MDMSc, Vishal Kukreti, MD FRCP(C), Michael Crump, MD, Melania Pintilie, MSc, John Kuruvilla, MD

Blood (2017) 130 (Supplement 1): 4156.

https://doi.org/10.1182/blood.V130.Suppl_1.4156.4156

Published: 2017

Journal Articles

Potential Utility of Event-Free Survival (EFS) As Surrogate Endpoint for Overall Survival (OS) in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) after Autologous Stem Cell Transplantation (ASCT): A Subgroup Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Randomized Phase III Trial

Shen Li, MD, Annette E Hay, Michael Crump, MD, Peter Anglin, MD FRCPC, MBA, Tara Baetz, Ralph Meyer, MDFRCPC, Armand Keating, MD, Sue Robinson, MD, Matthew Seftel, MRCP, MD MPH, FRCPC, Caterina Stelitano, Marina S Djurfeldt, MSc, Lois E. Shepherd, Bingshu E. Chen, Sarit Assouline, MD

Blood (2017) 130 (Supplement 1): 2015.

https://doi.org/10.1182/blood.V130.Suppl_1.2015.2015

Published: 2017

Journal Articles

HBV Care Map for Patients Receiving Anti-CD20 Therapy

Zachary Liederman, MD, Neil Berinstein, MD, Michael Crump, MD, Jessica Hwang, MD MPH, Harry L.A. Janssen, PhD MD, C. Tom Kouroukis, MDMSc,FRCPC, Patricia Leung, Anna Lok, MD, Colina Yim, Andrew D. Zelenetz, MD PhD, Kelvin Chan, MD PhD, Jordan Feld, MD MPH, Lisa K. Hicks, MD MSc

Blood (2017) 130 (Supplement 1): 4697.

https://doi.org/10.1182/blood.V130.Suppl_1.4697.4697

Published: 2017

Journal Articles

Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Anca Prica, MD FRCP(C), Annette E Hay, Michael Crump, MD, Nicole Mittman, Lois E. Shepherd, Ralph Meyer, MDFRCPC, Kevin Imrie, MD, Nancy A. Risebrough, Marina S Djurfeldt, MSc, Bingshu E. Chen, Matthew Cheung, MD MS, FRCP

Blood (2017) 130 (Supplement 1): 4673.

https://doi.org/10.1182/blood.V130.Suppl_1.4673.4673

Published: 2017

Journal Articles

A Comparison of One Year Outcomes in ZUMA-1 (axicabtagene ciloleucel) and SCHOLAR-1 in Patients with Refractory, Aggressive Non-Hodgkinlymphoma (NHL)

Sattva S. Neelapu, MD, Frederick L. Locke, MD, Nancy L. Bartlett, MD, Lazaros J. Lekakis, MD, Patrick M. Reagan, MD, David B. Miklos, MD PhD, Caron A. Jacobson, MD, Ira Braunschweig, MD, Olalekan O. Oluwole, MBBS, MPH, Tanya Siddiqi, MD, Yi Lin, MD PhD, Michael Crump, MD, John Kuruvilla, MD, Eric W. Van Den Neste, MD PhD, Umar Farooq, MD, Lynn Navale, MS, William Y. Go, MD PhD, Jeffrey S. Wiezorek, MD MS, Christian Gisselbrecht

Blood (2017) 130 (Supplement 1): 579.

https://doi.org/10.1182/blood.V130.Suppl_1.579.579

Published: 2017

NARROW

A Prospective Economic Analysis of Canadian Cancer Trials Group Clc.2/Alliance A041202: A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia

The Copy Number Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma

SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma

The Impact of Age on the Outcome of Primary Treatment for Classical Hodgkin's Lymphoma: 70 Years of Age Is a Clinical Relevant Cutpoint and the Most Important Predictor of Overall Survival

Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial

Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation

A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma

Recurrent Patterns of Clonal Evolution in Relapsed-Refractory DLBCL Following Treatment with R-CHOP

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

Event-Free Survival As a Surrogate for Overall Survival in Relapsed DLBCL after Autologous Transplant: A Subgroup Analysis of LY.12 and Coral

Evaluation of Unexplained Lymphadenopathy and Suspected Lymphoma in a Lymphoma Rapid Diagnostic Clinic

Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma

Prognostic Significance of Neutrophil to Lymphocyte Ratio (NLR) in Relapsed/Refractory Aggressive Lymphoma Salvage Chemotherapy — Analysis of Canadian Cancer Trials Group (CCTG) ly.10 Trial

Prolonged Overall Survival (OS) in a Subset of Responders to the Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL): Results of an International Multi- Center Phase I/II Experience

Treatment Outcomes in the Management of Lymphoblastic Lymphoma (LBL) in Adults: An Institutional Review

Potential Utility of Event-Free Survival (EFS) As Surrogate Endpoint for Overall Survival (OS) in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) after Autologous Stem Cell Transplantation (ASCT): A Subgroup Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Randomized Phase III Trial

HBV Care Map for Patients Receiving Anti-CD20 Therapy

Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

A Comparison of One Year Outcomes in ZUMA-1 (axicabtagene ciloleucel) and SCHOLAR-1 in Patients with Refractory, Aggressive Non-Hodgkinlymphoma (NHL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only